259 filings
Page 4 of 13
8-K
kxd1jn11 wud7tbqy
24 Feb 22
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
z0bzz 5wr7lic
16 Feb 22
Other Events
7:00am
8-K
50db2 jt8
10 Jan 22
Regulation FD Disclosure
7:31am
S-3ASR
ay1mg
17 Dec 21
Automatic shelf registration
12:00am
8-K
78pn gsix6txkm
1 Dec 21
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
7:00am
8-K
xb26xru ia5edd
2 Nov 21
Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
7:30am
8-K
7qbh0q6 gwsi9vbb
19 Oct 21
Other Events
8:01am
8-K
szlvfbostq9ip4
3 Aug 21
Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
7:01am
8-K
2syu2oy5da mqodj
15 Jun 21
Other Events
6:50am
8-K
rlwn77pe
10 Jun 21
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
pkvbdrrwbkil8lif3
4 May 21
Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
7:14am
DEFA14A
yb30c
29 Apr 21
Additional proxy soliciting materials
4:09pm
8-K
s74 xu9pkxm8bc8z4
12 Apr 21
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
7:17am
8-K
4ybj2n8dubv c3
18 Mar 21
Sage Therapeutics Announces Continued Positive Zuranolone Data for Both
6:55am
8-K
x2xpzy7 jvrf
17 Mar 21
Departure of Directors or Certain Officers
8:04am
S-8
cvhgm
24 Feb 21
Registration of securities for employees
7:46am